IP Library Granted Patent US 10,561,630
Granted Patent B2
US 10,561,630 · App. 15/730,011 · Granted Feb 18, 2020

Hydroxycitric acid compounds and capsule liquid delivery

Inventors: Dallas L. Clouatre (Seattle, WA); Daniel E. Clouatre (Seattle, WA)
Assignee: GLYKON TECHNOLOGIES GROUP, LLC
A61K31/225A61K9/08A61K9/2054A61K9/48A61K9/4808A61K9/4816A61K9/4825A61K9/4858A61K9/5057A61K47/10A61K47/12A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,561,630
App. No.
15/730,011
Granted
Feb 18, 2020
Kind
B2
Abstract

A capsule oral delivery system is disclosed. The system includes an outer capsule completely enclosing an inner content, or a hard shell comprised of hydroxypropyl methylcellulose (HPMC) enclosing the content. A liquid formulation forming the inner content of the outer capsule is comprised of a hydroxycitric acid (HCA) salt, water, and glycerol, with the HCA being completely dissolved in the water and glycerol which may be the only components present in the capsule, which may be administered to a patient in a method of treatment to cause weight loss when repeatedly administered.

Claims (14)

1. A gelatin capsule oral delivery system, comprising:

an outer capsule comprised of gelatin completely enclosing an inner content;

a liquid formulation forming the inner content of the outer capsule, the formulation consisting essentially of a salt of hydroxycitric acid (HCA), water, and glycerol, whereby the HCA salt is completely dissolved in the water and glycerol;

wherein the liquid formulation is prepared by mixing glycerol in water wherein the glycerol is present in an amount of about 1 to 3 parts by volume and the water is present in an amount of about 3 to 1 parts by volume to create a solution;

dissolving hydroxycitrate salt in the solution wherein the hydroxycitrate salt is present in a concentration ranging from about 1.1 to 1.7 molar dosage.

2. The gelatin capsule oral delivery system of claim 1 wherein the hydroxycitrate salt is a stable hydroxycitrate salt selected from a group consisting of sodium, potassium, potassium-magnesium or magnesium hydroxycitrate; double- or triple-metal salts based on the counter ions selected from the group consisting of magnesium, potassium and sodium; and any workable combination thereof.

3. The gelatin capsule oral delivery system of claim 2 , wherein the hydroxycitrate salt is a potassium-magnesium salt of ( )-hydroxycitric acid and is present in an amount of 750 mg.

4. A hydroxypropyl methylcellulose capsule oral delivery system, comprising:

an outer capsule comprised of hydroxypropyl methylcellulose completely enclosing an inner content;

a liquid formulation forming the inner content of the outer capsule, the formulation consisting essentially of a potassium-magnesium salt of hydroxycitric acid (HCA), water, and glycerol, whereby the HCA salt is completely dissolved in the water and glycerol;

wherein the liquid formulation is prepared by mixing glycerol in water wherein the glycerol is present in an amount of about 1 to 3 parts by volume and the water is present in an amount of about 3 to 1 parts by volume to create a solution;

dissolving hydroxycitrate salt in the solution wherein the hydroxycitrate salt is present in a concentration ranging from about 1.1 to 1.7 molar dosage.

5. The hydroxypropyl methylcellulose capsule oral delivery system of claim 4 wherein the hydroxycitrate salt is a stable hydroxycitrate salt selected from a group consisting of sodium, potassium, potassium-magnesium or magnesium hydroxycitrate; double- or triple-metal salts based on the counter ions selected from the group consisting of magnesium, potassium and sodium; and any workable combination thereof.

6. The hydroxypropyl methylcellulose capsule oral delivery system of claim 4 , wherein the hydroxycitrate salt is a potassium-magnesium salt of ( )-hydroxycitric acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 5, 2022
From: GLYKON TECHNOLOGIES GROUP, LLC
To: NUTRITION RESEARCH GROUP, LIMITED
Reel/Frame 058559/0645 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 2, 2017
From: CLOUATRE, DANIEL E.; CLOUATRE, DALLAS L.
To: GLYKON TECHNOLOGIES GROUP, LLC
Reel/Frame 044022/0558 →
Continuity (2)
Provisional Application 62412393 · Oct 25, 2016
Related Publication 20180110750A1 · Apr 26, 2018